Everolimus has shown potential to enhance immune function in individuals in their mid-60s.

“so so that study so everolimus is a derivative of rapamycin and and biochemically it has exactly the same mechanism so it's i at least i conceptually think about them as essentially the same molecule so so anything that we see with ever alignments we would expect to see with rapamycin and so that was a phase two clinical trial in healthy older adults to look at whether or not a six-week uh treatment with everelymus could boost uh vaccine response”

“the first paper what the first paper showed was I think pretty convincing data that at least at the five milligrams once a week and one milligram daily dose there was a boost in response to the vaccine as measured by antibody tighters so that supported the idea that similar to what had been shown in mice you could in fact to some extent rejuvenate the ability of the Aged immune system in humans to respond to a vaccine um with transient dosing with a Romy derivative ever in this case”

“we have this one study using everus that show that gives us a hint that says hey this might actually enhance immune function in people in their mid-60s”